A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR
暂无分享,去创建一个
W. Kremers | M. Hopp | D. Dupoiron | A. Ellery | B. Bosse | O. Loewenstein | A. Stachowiak